# Bioheng

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioheng

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.bioheng.com
- Total disclosed funding: $94M
- Latest round: Series B (Mar 25, 2021)
- Investors on record: 5

## About

Established in 2017 and based in Nanjing, China, Bioheng Therapeutics focuses on developing allogeneic CAR-T therapies, utilizing advanced technology to provide innovative cancer treatments.Bioheng Therapeutics is dedicated to the development of allogeneic 'off-the-shelf' CAR-T therapies. The company was founded by Lu Han and Xiaohong He. As of March 2021, Bioheng raised RMB 520 million in Series B funding from investors including GL Ventures and Octagon Capital Investments, bringing total funding raised to RMB 520 million. The company is headquartered in Nanjing, China and has completed 3 deals, with its most recent deal occurring on March 25, 2021.Bioheng Therapeutics specializes in the development of allogeneic 'off-the-shelf' universal CAR-T therapies, leveraging its proprietary UCAR-T technology platform known as ANSWER®. Their primary products, including the CD7-targeted UCAR-T therapy CTD40X, address unmet needs in treating hematological malignancies, particularly T-cell acute lymphoblastic leukemia (T-ALL). Bioheng received Investigational New Drug (IND) approval for CTA101 in March 2022, and its therapeutic products are in advanced clinical trials aimed at enhancing treatment efficacy. The company targets healthcare providers, hospitals, and research institutions involved in oncology and autoimmune disease treatment globally, including markets in the United States and China.Bioheng Therapeutics generates revenue through partnerships and collaborations with healthcare institutions and pharmaceutical partners focused on innovative therapeutic solutions for cancer and autoimmune diseases. The company’s revenue streams are structured around agreements for clinical trial collaborations, which involve funding for research and development phases in exchange for future access to Bioheng's proprietary therapies. The pricing of its UCAR-T products reflects their advanced therapeutic capabilities and the robust clinical data supporting their efficacy and safety profiles, particularly for its flagship products, CTA101 and CTD40X.Bioheng plans to utilize its recent funding of RMB 520 million raised in March 2021 to support the advancement of its product pipeline, including the ongoing development and clinical trials of CTA101 and CTD40X. The company intends to expand its market presence in the United States and potentially other international markets by 2023, aiming to enhance access to its innovative CAR-T therapies. The funding will aid in accelerating product development and expediting market entry strategies.

## Funding rounds

- Series B, Mar 25, 2021, $80M — BlueRun Ventures, Decheng Capital, Shenzhen Capital Real Estate Fund, GL Ventures, Octagon Capital Investments
- Series A, Feb 14, 2019, $15M — Decheng Capital

## Investors

- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series A, Series B
- BlueRun Ventures (https://capitalatlas.ai/funds/bluerun-ventures) — Series B
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series B
- Octagon Capital Investments (https://capitalatlas.ai/funds/octagon-capital-investments) — Series B